Journal article

Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial

Wesley H Self, Matthew W Semler, Rinaldo Bellomo, Samuel M Brown, Bennett P deboisblanc, Matthew C Exline, Adit A Ginde, Colin K Grissom, David R Janz, Alan E Jones, Kathleen D Liu, Stephen PJ Macdonald, Chadwick D Miller, Pauline K Park, Lora A Reineck, Todd W Rice, Jay S Steingrub, Daniel Talmor, Donald M Yealy, Ivor S Douglas Show all

Annals of Emergency Medicine | MOSBY-ELSEVIER | Published : 2018

University of Melbourne Researchers


Awarded by National Heart, Lung, and Blood Institute U01

Awarded by National Institute of General Medical Sciences



Funding Acknowledgements

By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see This work was supported by National Heart, Lung, and Blood Institute U01 grants HL123009, HL123010, HL123004, HL123022, HL122989, HL123008, HL123027, HL123020, HL123018, HL123031, HL123033, HL122998, and HL123023. Dr. Self was supported in part by K23GM110469 from the National Institute of General Medical Sciences. All authors are supported by the National Heart, Lung, and Blood Institute within the National Institutes of Health (NIH) for participation in the Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. Dr. Self reports receiving grants from Cheetah Medical; consultant fees from Abbott Point of Care, Cempra Pharmaceuticals, Ferring Pharmaceuticals, and BioTest AG; and travel funds from Gilead Sciences and Pfizer. Dr. Brown reports receiving fees from Faron Pharmaceuticals for serving on a steering committee for a clinical trial in acute respiratory distress syndrome. Dr. Ginde reports receiving consulting fees from the Coalition for Sepsis Survival (a nonprofit foundation) to develop sepsis-related algorithms. Dr. Liu reports stock ownership with Amgen; receiving consultant fees from Achaogen, Durect, Z S Pharma, Theravance, Quark, and Potrero Medical; receiving travel funds from the American Society of Nephrology and National Policy Forum on Critical Care and Acute Renal Failure; and receiving compensation for an editorial position from the National Kidney Foundation. Dr. Miller reports receiving grants from Abbott, Ferring, Siemens, as well as software from Siemens. Dr. Rice reports receiving consultant fees from Cumberland Pharmaceuticals, Inc, and personal fees from Avisa Pharma, LLC. Dr. Douglas reports a relationship with Cheetah Medical in which he is principal investigator for an industry-sponsored sepsis trial; payments for his principal investigator role and study-site enrollment are to his employer, an academic hospital. Dr. Shapiro reports receiving research funding from the NIH, Siemens, Lajolla Pharmaceuticals, and ThermoFisher, as well as advisory board income from Baxter.